ArticleBMC gastroenterology2025
Clinical characteristics of familial and sporadic inflammatory bowel disease in Egyptian patients.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial aggregation of inflammatory bowel disease (IBD) has been observed, but data from the Middle East, particularly Egypt, remain limited. This study investigated clinical differences, treatment responses, and predictors of response in familial and sporadic IBD patients.
methodsThis case‒control study was conducted on ninety IBD patients (30 familial, 60 sporadic). Clinical history, inflammatory markers, endoscopic findings, and treatment outcomes were analysed over a one-year period. Predictors of response and mucosal healing were assessed via logistic regression.
resultsMucosal healing was achieved in a greater percentage of patients in the familial group (73.3%) compared to those in the sporadic group (55%), but the difference did not reach statistical significance (P = 0.093). The percentages of patients with mucosal healing, clinical response, clinical remission and normalization of C-reactive protein (CRP) levels at one year were significantly greater in ulcerative patients in the familial group [17 (85%), 18 (90%), 18 (90%) and 18 (90%), respectively] than in ulcerative patients in the sporadic group [21 (53.8%), 19 (48.7%), 19 (48.7%) and 20 (51.3%), respectively], with p values of 0.018, 0.002, 0.002 and 0.003, respectively. However, there was no statistically significant difference between Crohn's disease patients of both groups regarding the outcome of the studied patients. A lower platelet count (≤ 324 × 10³/µL) and faecal calprotectin concentration (≤ 679 µg/g) were significant predictors of mucosal healing in familial cases (P = 0.012, P = 0.008, respectively).
conclusionFamilial IBD patients may present with a more severe initial inflammatory response but have better long-term treatment outcomes. These findings suggest that genetic and environmental influences play a role in IBD, highlighting the need for region-specific studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.